ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INTP Integrated Pharmaceuticals Inc (CE)

0.000001
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Integrated Pharmaceuticals Inc (CE) USOTC:INTP OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.00 01:00:00

- Termination of Registration of a Class of Security under Section 12(g) (15-12G)

12/11/2008 9:19pm

Edgar (US Regulatory)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
OMB Approval
OMB Number      3235-0167
Expires:  November 30, 2010
Estimated average burden
Hours per response ………1.50
Form 15

 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number:    000-50690



Integrated Pharmaceuticals, Inc.

(Exact Name of Registrant as specified in its charter)

 
310 Authority Drive
Fitchburg, MA 01420
(Address of principal executive offices) (Zip Code)

(978) 696-0020
(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changes since last report)


Common stock, $0.001 par value per share

(Title of each class of securities covered by this Form)


None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 
 
 
 
 

 


 
 
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)                                    ¨
Rule 12g-4(a)(2)                                    ¨
Rule 12h-3(b)(1)(i)                                ¨
Rule 12h-3(b)(1)(ii)                               þ
Rule 15d-6                                             ¨
 
Approximate number of holders of record as of the certification or notice date:   491


Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.


Date:      November 12, 2008                                                                             By:   /s/ Peter Featherston, President and CEO                 


Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.
 
 
 
 
 
 
 
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Integrated Pharmaceuticals (CE) Chart

1 Year Integrated Pharmaceuticals (CE) Chart

1 Month Integrated Pharmaceuticals (CE) Chart

1 Month Integrated Pharmaceuticals (CE) Chart